ShallowBench: Testing Generative AI's Limits in Drug Discovery

Generative AI in drug discovery has gained momentum, especially in designing molecules for deep binding sites. However, shallow-pocket targets like the elusive KRAS and MYC in oncology, these models hit a wall. The introduction of ShallowBench marks a important moment for testing AI's capabilities against such targets.

The ShallowBench Test

ShallowBench, a benchmark extracted from CrossDocked2020, comprises 5,780 targets with shallow pockets. The approach involves calculating the difference between an Alpha Shape 'lid' volume and the protein atom voxel volume. This isolates targets characterized by low concavity but with enough surface area for potential binding. These aren't just any targets, they're the ones where traditional methods and AI alike have struggled to gain a foothold.

AI Models on the Bench

When tested on ShallowBench, leading generative models showed weaker binding affinities on targets with low concavity interfaces. It's clear that the current architectures aren't cutting it. So what's the takeaway here? Generative AI needs a reboot, or at least a major tune-up, to navigate these tricky landscapes. New architectural innovations or loss functions are the call of the day.

Why This Matters

Why should developers and researchers care? Because the oncology targets KRAS and MYC aren't just buzzwords, they're critical in the fight against cancer. If AI can't tackle these, its promise in drug discovery is limited. Are we seeing the boundaries of AI's potential, or just the beginning of a new frontier? Developers need to rethink their strategies, focusing on innovative ways to enhance binding affinity predictions for these challenging targets.

ShallowBench isn't just a benchmark, it's a call to action. For those in the AI and biotech fields, it's time to clone the repo, run the test, and think critically about how to push these systems forward. The field demands nothing less than disruptive innovation.